Banque Transatlantique SA Acquires New Holdings in Pfizer Inc. (NYSE:PFE)

Banque Transatlantique SA purchased a new stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 67,006 shares of the biopharmaceutical company's stock, valued at approximately $1,768,000.

A number of other hedge funds and other institutional investors also recently modified their holdings of PFE. Retirement Wealth Solutions LLC acquired a new position in shares of Pfizer in the 4th quarter worth approximately $26,000. Rialto Wealth Management LLC acquired a new stake in shares of Pfizer during the 4th quarter valued at $26,000. Kohmann Bosshard Financial Services LLC acquired a new stake in shares of Pfizer during the fourth quarter worth $28,000. Noble Wealth Management PBC purchased a new stake in shares of Pfizer during the fourth quarter valued at $31,000. Finally, Bernard Wealth Management Corp. acquired a new position in shares of Pfizer in the 4th quarter valued at $33,000. Institutional investors own 68.36% of the company's stock.

Pfizer Stock Performance

PFE traded down $0.95 on Tuesday, hitting $22.92. The company had a trading volume of 60,727,463 shares, compared to its average volume of 40,495,405. The stock has a market cap of $129.97 billion, a price-to-earnings ratio of 16.25, a price-to-earnings-growth ratio of 0.64 and a beta of 0.58. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The company's fifty day moving average price is $24.29 and its 200 day moving average price is $25.69. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, topping analysts' consensus estimates of $0.67 by $0.25. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company had revenue of $13.72 billion during the quarter, compared to analyst estimates of $14.43 billion. During the same period in the previous year, the company earned $0.82 earnings per share. The company's quarterly revenue was down 7.8% compared to the same quarter last year. Equities analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 13th. Shareholders of record on Friday, May 9th will be paid a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 7.51%. The ex-dividend date is Friday, May 9th. Pfizer's dividend payout ratio is 124.64%.

Wall Street Analyst Weigh In

Several brokerages have commented on PFE. Guggenheim reiterated a "buy" rating on shares of Pfizer in a report on Tuesday, March 18th. UBS Group lifted their price objective on shares of Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a research report on Wednesday, April 30th. Citigroup restated a "neutral" rating on shares of Pfizer in a report on Thursday, March 27th. Hsbc Global Res upgraded Pfizer to a "strong-buy" rating in a report on Monday, March 10th. Finally, Cantor Fitzgerald started coverage on Pfizer in a research note on Tuesday, April 22nd. They issued a "neutral" rating and a $24.00 price objective for the company. One analyst has rated the stock with a sell rating, eight have issued a hold rating, four have given a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat.com, Pfizer has an average rating of "Moderate Buy" and an average price target of $29.17.

Insider Buying and Selling at Pfizer

In other news, Director Ronald E. Blaylock acquired 19,457 shares of the firm's stock in a transaction on Thursday, February 13th. The shares were purchased at an average cost of $25.65 per share, with a total value of $499,072.05. Following the completion of the purchase, the director now owns 27,707 shares of the company's stock, valued at $710,684.55. This represents a 235.84 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 0.06% of the company's stock.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.